http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2580640-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ba4122ede75338f54ef0c5e483a42c70 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-48 |
| filingDate | 2014-12-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_86db5f49a0ed4fbeb9916ff6b1a2e21c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6874d46b442814965408b2fd68a4cb03 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_13c88c9414d322b626c3041e5f2b44ca http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b33cfdc95bbc5915688659c5ab9db532 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ad9d2287fcab7d4ef929e280b5b88a8c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e968be8b1ffd56f968f62f88cda6852c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9aa4e9746339517a7767e7cded5b6cbd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_981f43d0b6726c9e58c40f1bdba28cd5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_90dcf30e9ed0c4885de793c7f6fa078d |
| publicationDate | 2016-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2580640-C1 |
| titleOfInvention | Method for preventing humoral rejection in case of abo incompatibility of liver transplantation in young children |
| abstract | FIELD: medicine. n SUBSTANCE: invention relates to transplant, it may be used in preparing young children to the ABO-incompatible liver transplantation. Titer reduction of group-specific antibodies is carried out by daily transfusions of fresh frozen plasma group AB(IV) in a volume of 60-300 ml. Control group specific titers of antibodies capable of reacting with group agglutination antigens of the donor and transplantation is performed when the allowable level for transplantation controlled antibodies. Acceptable for transplantation titer of antibodies find natural group-specific antibodies is not more than 1:8, group-titer immune complete antibodies not more than 1:4 and incomplete group-immune titers of antibodies is not more than 1:4. n EFFECT: technical result achieved when exercising this inventive method consists in the prevention of complications caused by plasmapheresis, while maintaining a reliable high titer reduction of group-specific antibodies prior to transplantation, reducing the cost of the process, its availability. n 3 cl, 3 ex |
| priorityDate | 2014-12-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 41.